# Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

> **NCT04298372** · PHASE3 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 2 (actual)

## Conditions studied

- Amyloidosis Cardiac

## Interventions

- **DRUG:** Lenalidomide 25mg

## Key facts

- **NCT ID:** NCT04298372
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-20
- **Primary completion:** 2021-11-25
- **Final completion:** 2021-11-25
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04298372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04298372, "Frontline Lenalidomide for AL Amyloidosis Involving Myocardium". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04298372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*